Has Glenmark Pharma declared dividend?
Yes, Glenmark Pharmaceuticals has declared a 250% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024. The company has shown strong total returns over various periods, particularly in the long term.
Glenmark Pharmaceuticals Ltd. has declared a 250% dividend.Dividend Details:
- Percentage announced: 250%
- Amount per share: 2.5
- Ex-date: 13 Sep 24
Dividend Yield: 0.16%.
Total Returns by Period:
In the last 6 months, the price return was 3.97%, with no dividend return, resulting in a total return of 3.97%.
Over the past year, the price return was 31.68%, with a dividend return of 0.21%, leading to a total return of 31.89%.
In the 2-year period, the price return was 152.58%, with a dividend return of 0.78%, culminating in a total return of 153.36%.
For the 3-year period, the price return was 305.84%, with a dividend return of 2.04%, resulting in a total return of 307.88%.
In the last 4 years, the price return was 159.41%, with a dividend return of 1.50%, giving a total return of 160.91%.
Over the 5-year period, the price return was 295.81%, with a dividend return of 2.87%, leading to a total return of 298.68%.
Overall, Glenmark Pharma has declared a substantial dividend, and the total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting a positive performance trend for the company.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Activity
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Most Read
